Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants
Background and Aims: The clinical characteristics and risk factors involved in the development of liver fibrosis in the subtypes of steatotic liver disease (SLD) remain unknown. We examined the clinical characteristics of SLD subtypes using a large Japanese cohort. Methods: We performed a cross-sect...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572324001213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265656692310016 |
|---|---|
| author | Yoshihiro Kamada Hideki Fujii Yuichiro Suzuki Koji Sawada Miwa Tatsuta Tatsuji Maeshiro Hiroshi Tobita Tsubasa Tsutsumi Takemi Akahane Chitomi Hasebe Miwa Kawanaka Takaomi Kessoku Yuichiro Eguchi Hayashi Syokita Atsushi Nakajima Tomoari Kamada Hitoshi Yoshiji Takumi Kawaguchi Hiroshi Sakugawa Asahiro Morishita Tsutomu Masaki Takumi Ohmura Toshio Watanabe Yoshioki Yoda Nobuyuki Enomoto Masafumi Ono Kanako Fuyama Kazufumi Okada Naoki Nishimoto Yoichi M. Ito Hirokazu Takahashi Yoshio Sumida |
| author_facet | Yoshihiro Kamada Hideki Fujii Yuichiro Suzuki Koji Sawada Miwa Tatsuta Tatsuji Maeshiro Hiroshi Tobita Tsubasa Tsutsumi Takemi Akahane Chitomi Hasebe Miwa Kawanaka Takaomi Kessoku Yuichiro Eguchi Hayashi Syokita Atsushi Nakajima Tomoari Kamada Hitoshi Yoshiji Takumi Kawaguchi Hiroshi Sakugawa Asahiro Morishita Tsutomu Masaki Takumi Ohmura Toshio Watanabe Yoshioki Yoda Nobuyuki Enomoto Masafumi Ono Kanako Fuyama Kazufumi Okada Naoki Nishimoto Yoichi M. Ito Hirokazu Takahashi Yoshio Sumida |
| author_sort | Yoshihiro Kamada |
| collection | DOAJ |
| description | Background and Aims: The clinical characteristics and risk factors involved in the development of liver fibrosis in the subtypes of steatotic liver disease (SLD) remain unknown. We examined the clinical characteristics of SLD subtypes using a large Japanese cohort. Methods: We performed a cross-sectional analysis (total n = 108,446). In this cohort, SLD was diagnosed by ultrasonography. Individuals with none of the cardiometabolic risk factors were excluded. Results: According to their nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) status based on the database, participants with cardiometabolic criteria were allocated to the MASLD, MASLD with increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) with metabolic dysfunction groups. Of 30,857 subjects with SLD, 21,488 (69.6%) had NAFLD, and 20,922 (67.8%) had MASLD. There were few differences in the clinical characteristics between NAFLD and MASLD. After adjustment for clinical variables, we found that male patients with MetALD [odds ratio (OR) 2.26; 95% confidence interval (CI) 1.87–2.84] and ALD with metabolic dysfunction (OR 3.92; 95% CI 2.85–5.39) had a significantly higher risk for advanced liver fibrosis (diagnosed by Fibrosis-4 (FIB-4) index >2.67) compared to those with MASLD. In female patients with ALD, metabolic dysfunction (OR 5.80; 95% CI 2.51–13.4) and systemic blood pressure of ≥130 mmHg were significant risk factors for high FIB-4 (males: OR 3.38, 95% CI 2.51–4.55; females: OR 4.34, 95% CI 2.66–7.07, P < .001). Conclusion: Alcohol intake and systolic blood pressure are independent contributors to liver fibrosis progression assessed by FIB-4 in SLD. |
| format | Article |
| id | doaj-art-8fc46b5475d448f3bd4a95a12cbd8638 |
| institution | OA Journals |
| issn | 2772-5723 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj-art-8fc46b5475d448f3bd4a95a12cbd86382025-08-20T01:54:21ZengElsevierGastro Hep Advances2772-57232024-01-01381148115610.1016/j.gastha.2024.08.006Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup ParticipantsYoshihiro Kamada0Hideki Fujii1Yuichiro Suzuki2Koji Sawada3Miwa Tatsuta4Tatsuji Maeshiro5Hiroshi Tobita6Tsubasa Tsutsumi7Takemi Akahane8Chitomi Hasebe9Miwa Kawanaka10Takaomi Kessoku11Yuichiro Eguchi12Hayashi Syokita13Atsushi Nakajima14Tomoari Kamada15Hitoshi Yoshiji16Takumi Kawaguchi17Hiroshi Sakugawa18Asahiro Morishita19Tsutomu Masaki20Takumi Ohmura21Toshio Watanabe22Yoshioki Yoda23Nobuyuki Enomoto24Masafumi Ono25Kanako Fuyama26Kazufumi Okada27Naoki Nishimoto28Yoichi M. Ito29Hirokazu Takahashi30Yoshio Sumida31Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine 1-7, Suita, Osaka, JapanDepartment of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Osaka, Japan; Correspondence: Address correspondence to: Hideki Fujii, MD, PhD, Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3, Asahimachi, Abeno, Osaka 545–8585, Japan.Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Chuo-shi, Yamanashi, JapanDivision of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa-city, Hokkaido, JapanDepartment of Gastroenterology, KKR Takamatsu Hospital 4-18 Tenjinmae, Takamatsu, Kagawa, JapanFirst Department of Internal Medicine, University of the Ryukyus Hospital, Nakagami, Okinawa, JapanDepartment of Hepatology, Shimane University Hospital, Izumo, Shimane, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, JapanDepartment of Gastroenterology, Nara Medical University, Kashihara, Nara, JapanDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa-city, Hokkaido, JapanDepartment of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Kita, Okayama, JapanKanagawa Dental University Yokohama Clinic, Yokohama, Kanagawa, Japan; Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, Narita-shi, Chiba, Japan; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, JapanLoco Medical General Institute, Ogi, Saga, JapanDepartment of Gastroenterology, Northern OKINAWA Medical Center, Nago, Okinawa, JapanDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, JapanDepartment of Health Care Medicine, Kawasaki Medical School, Kita, Okayama, JapanDepartment of Gastroenterology, Nara Medical University, Kashihara, Nara, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, JapanDepartment of Gastroenterology, Heartlife Hospital, Nakagami, Okinawa, JapanFaculty of Medicine, Department of Gastroenterology and Neurology, Kagawa University, Kita-gun, Kagawa, JapanFaculty of Medicine, Department of Gastroenterology and Neurology, Kagawa University, Kita-gun, Kagawa, JapanDepartment of Health Care, Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, JapanDepartment of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Osaka, JapanJA Yamanashi Koseiren Health Care Center, Kofu, Yamanashi, JapanDepartment of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Chuo-shi, Yamanashi, JapanDivision of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Mikicho, Kagawa, JapanData Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Hokkaido, JapanData Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Hokkaido, JapanData Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Hokkaido, JapanData Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Hokkaido, JapanLiver Center, Saga University Hospital, Saga, Saga, JapanGraduate School of Healthcare Management, International University of Healthcare and Welfare, Minatoku, Tokyo, JapanBackground and Aims: The clinical characteristics and risk factors involved in the development of liver fibrosis in the subtypes of steatotic liver disease (SLD) remain unknown. We examined the clinical characteristics of SLD subtypes using a large Japanese cohort. Methods: We performed a cross-sectional analysis (total n = 108,446). In this cohort, SLD was diagnosed by ultrasonography. Individuals with none of the cardiometabolic risk factors were excluded. Results: According to their nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) status based on the database, participants with cardiometabolic criteria were allocated to the MASLD, MASLD with increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) with metabolic dysfunction groups. Of 30,857 subjects with SLD, 21,488 (69.6%) had NAFLD, and 20,922 (67.8%) had MASLD. There were few differences in the clinical characteristics between NAFLD and MASLD. After adjustment for clinical variables, we found that male patients with MetALD [odds ratio (OR) 2.26; 95% confidence interval (CI) 1.87–2.84] and ALD with metabolic dysfunction (OR 3.92; 95% CI 2.85–5.39) had a significantly higher risk for advanced liver fibrosis (diagnosed by Fibrosis-4 (FIB-4) index >2.67) compared to those with MASLD. In female patients with ALD, metabolic dysfunction (OR 5.80; 95% CI 2.51–13.4) and systemic blood pressure of ≥130 mmHg were significant risk factors for high FIB-4 (males: OR 3.38, 95% CI 2.51–4.55; females: OR 4.34, 95% CI 2.66–7.07, P < .001). Conclusion: Alcohol intake and systolic blood pressure are independent contributors to liver fibrosis progression assessed by FIB-4 in SLD.http://www.sciencedirect.com/science/article/pii/S2772572324001213Metabolic DysfunctionAlcohol IntakeSystolic Blood PressureSteatotic Liver DiseaseFIB-4 Index |
| spellingShingle | Yoshihiro Kamada Hideki Fujii Yuichiro Suzuki Koji Sawada Miwa Tatsuta Tatsuji Maeshiro Hiroshi Tobita Tsubasa Tsutsumi Takemi Akahane Chitomi Hasebe Miwa Kawanaka Takaomi Kessoku Yuichiro Eguchi Hayashi Syokita Atsushi Nakajima Tomoari Kamada Hitoshi Yoshiji Takumi Kawaguchi Hiroshi Sakugawa Asahiro Morishita Tsutomu Masaki Takumi Ohmura Toshio Watanabe Yoshioki Yoda Nobuyuki Enomoto Masafumi Ono Kanako Fuyama Kazufumi Okada Naoki Nishimoto Yoichi M. Ito Hirokazu Takahashi Yoshio Sumida Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants Gastro Hep Advances Metabolic Dysfunction Alcohol Intake Systolic Blood Pressure Steatotic Liver Disease FIB-4 Index |
| title | Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants |
| title_full | Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants |
| title_fullStr | Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants |
| title_full_unstemmed | Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants |
| title_short | Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants |
| title_sort | clinical characteristics of steatotic liver disease categories in a large cohort of japanese health checkup participants |
| topic | Metabolic Dysfunction Alcohol Intake Systolic Blood Pressure Steatotic Liver Disease FIB-4 Index |
| url | http://www.sciencedirect.com/science/article/pii/S2772572324001213 |
| work_keys_str_mv | AT yoshihirokamada clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hidekifujii clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT yuichirosuzuki clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT kojisawada clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT miwatatsuta clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT tatsujimaeshiro clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hiroshitobita clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT tsubasatsutsumi clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT takemiakahane clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT chitomihasebe clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT miwakawanaka clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT takaomikessoku clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT yuichiroeguchi clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hayashisyokita clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT atsushinakajima clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT tomoarikamada clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hitoshiyoshiji clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT takumikawaguchi clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hiroshisakugawa clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT asahiromorishita clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT tsutomumasaki clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT takumiohmura clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT toshiowatanabe clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT yoshiokiyoda clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT nobuyukienomoto clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT masafumiono clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT kanakofuyama clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT kazufumiokada clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT naokinishimoto clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT yoichimito clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT hirokazutakahashi clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants AT yoshiosumida clinicalcharacteristicsofsteatoticliverdiseasecategoriesinalargecohortofjapanesehealthcheckupparticipants |